Does the media favor ADMA or MPLT?

In the previous week, Maplight Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat Maplight Therapeutics' score of 0.58 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AUPH or MPLT?

In the previous week, Maplight Therapeutics had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for Maplight Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Maplight Therapeutics' average media sentiment score of 0.58 beat Aurinia Pharmaceuticals' score of 0.20 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MPLT or RXRX?

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 14 mentions for Recursion Pharmaceuticals and 8 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.58 beat Recursion Pharmaceuticals' score of 0.26 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MPLT or BCRX?

In the previous week, Maplight Therapeutics had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for BioCryst Pharmaceuticals. Maplight Therapeutics' average media sentiment score of 0.58 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VCEL or MPLT?

In the previous week, Maplight Therapeutics had 4 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Maplight Therapeutics' score of 0.58 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Maplight Therapeutics (MPLT) Competitors

$8.83 -0.32 (-3.50%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.85 +0.02 (+0.17%)

As of 10/9/2026 07:30 PM Eastern

Compare

MPLT vs. ADMA, AUPH, RXRX, BCRX, and VCEL

Should you buy Maplight Therapeutics stock or one of its competitors? Maplight Therapeutics's main competitors and comparable companies include ADMA Biologics (ADMA), Aurinia Pharmaceuticals (AUPH), Recursion Pharmaceuticals (RXRX), BioCryst Pharmaceuticals (BCRX), and Vericel (VCEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maplight Therapeutics compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

ADMA Biologics has a net margin of 32.98% compared to Maplight Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Maplight Therapeutics	N/A	-98.60%	-60.33%

75.7% of ADMA Biologics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 80.18%. Maplight Therapeutics has a consensus target price of $29.50, suggesting a potential upside of 234.09%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maplight Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89

ADMA Biologics has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.55	$146.93M	$0.70	14.80
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

In the previous week, Maplight Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.59 beat Maplight Therapeutics' score of 0.58 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Maplight Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Aurinia Pharmaceuticals presently has a consensus price target of $17.67, indicating a potential upside of 6.11%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 234.09%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89

Aurinia Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.83	$287.20M	$2.29	7.27
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Maplight Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Maplight Therapeutics	N/A	-98.60%	-60.33%

In the previous week, Maplight Therapeutics had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 8 mentions for Maplight Therapeutics and 3 mentions for Aurinia Pharmaceuticals. Maplight Therapeutics' average media sentiment score of 0.58 beat Aurinia Pharmaceuticals' score of 0.20 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats Maplight Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Recursion Pharmaceuticals?

Maplight Therapeutics (NASDAQ:MPLT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Maplight Therapeutics. MarketBeat recorded 14 mentions for Recursion Pharmaceuticals and 8 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.58 beat Recursion Pharmaceuticals' score of 0.26 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 234.09%. Recursion Pharmaceuticals has a consensus target price of $8.06, suggesting a potential upside of 84.86%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Maplight Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Maplight Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Recursion Pharmaceuticals	$74.68M	31.25	-$644.76M	-$1.04	N/A

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Maplight Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Summary

Maplight Therapeutics beats Recursion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to BioCryst Pharmaceuticals?

Maplight Therapeutics (NASDAQ:MPLT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Maplight Therapeutics had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for BioCryst Pharmaceuticals. Maplight Therapeutics' average media sentiment score of 0.58 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics currently has a consensus price target of $29.50, indicating a potential upside of 234.09%. BioCryst Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 139.77%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Maplight Therapeutics is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
BioCryst Pharmaceuticals	$874.84M	2.50	$263.86M	-$1.50	N/A

Maplight Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Summary

Maplight Therapeutics beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Vericel has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$306.30M	6.70	$16.52M	$0.47	85.32
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

Vericel has a net margin of 7.91% compared to Maplight Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Vericel currently has a consensus price target of $58.40, indicating a potential upside of 45.64%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 234.09%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maplight Therapeutics	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.89

In the previous week, Maplight Therapeutics had 4 more articles in the media than Vericel. MarketBeat recorded 8 mentions for Maplight Therapeutics and 4 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Maplight Therapeutics' score of 0.58 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Maplight Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$508.52M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-0.21	13.42	274.15	26.16
Price / Sales	N/A	1,237.85	590.48	94.54
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.87	17.17	11.21	6.34
Net Income	-$161.15M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-10.08%	-1.33%	-0.90%	-1.41%
1 Month Performance	-35.92%	-8.44%	-4.44%	-3.48%
1 Year Performance	N/A	14.02%	6.96%	1.16%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	3.7918 of 5 stars	$8.83 -3.5%	$29.50 +234.1%	N/A	$508.52M	N/A	N/A	133
ADMA ADMA Biologics	4.0342 of 5 stars	$10.05 +0.9%	$18.67 +85.7%	-29.7%	$2.23B	$510.17M	14.36	647
AUPH Aurinia Pharmaceuticals	3.1581 of 5 stars	$16.22 -1.2%	$17.67 +8.9%	+43.3%	$2.18B	$283.05M	7.08	128	News Coverage
RXRX Recursion Pharmaceuticals	2.545 of 5 stars	$4.13 +2.5%	$8.06 +95.2%	-26.2%	$2.16B	$74.68M	N/A	600	Insider Trade
BCRX BioCryst Pharmaceuticals	2.9591 of 5 stars	$8.33 +0.7%	$20.50 +146.1%	+17.9%	$2.11B	$940.61M	N/A	435	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. ADMA, AUPH, RXRX, BCRX, and VCEL

How does Maplight Therapeutics compare to ADMA Biologics?

Summary

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Maplight Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does Maplight Therapeutics compare to BioCryst Pharmaceuticals?

Summary

How does Maplight Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. ADMA, AUPH, RXRX, BCRX, and VCEL

How does Maplight Therapeutics compare to ADMA Biologics?

Is ADMA or MPLT more profitable?

Do insiders and institutionals hold more shares of ADMA or MPLT?

Do analysts rate ADMA or MPLT?

Which has preferable valuation & earnings, ADMA or MPLT?

Does the media favor ADMA or MPLT?

Summary

How does Maplight Therapeutics compare to Aurinia Pharmaceuticals?

Do analysts prefer AUPH or MPLT?

Which has better earnings & valuation, AUPH or MPLT?

Do insiders and institutionals believe in AUPH or MPLT?

Is AUPH or MPLT more profitable?

Does the media favor AUPH or MPLT?

Summary

How does Maplight Therapeutics compare to Recursion Pharmaceuticals?

Does the media favor MPLT or RXRX?

Do analysts prefer MPLT or RXRX?

Which has higher earnings & valuation, MPLT or RXRX?

Do insiders and institutionals have more ownership in MPLT or RXRX?

Is MPLT or RXRX more profitable?

Summary

How does Maplight Therapeutics compare to BioCryst Pharmaceuticals?

Does the media prefer MPLT or BCRX?

Do analysts recommend MPLT or BCRX?

Do insiders & institutionals have more ownership in MPLT or BCRX?

Which has higher valuation and earnings, MPLT or BCRX?

Is MPLT or BCRX more profitable?

Summary

How does Maplight Therapeutics compare to Vericel?

Which has higher valuation and earnings, VCEL or MPLT?

Is VCEL or MPLT more profitable?

Do analysts recommend VCEL or MPLT?

Does the media favor VCEL or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools